Arecor Therapeutics PLC (AREC) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Arecor Therapeutics PLC stock £0.32, price £0.78, that is 58.7% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range £0.3800 – £4.50 · fair‑value band £0.2400 – £0.4000 · the £0.7750 price screens above the £0.3200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Arecor Therapeutics in your weekly email
Every Wednesday you see whether Arecor Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom.
Show moreShow less
The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist.
Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Stock analysis
Arecor Therapeutics PLC (AREC) currently trades at £0.7750, while our model-based Fair Value estimate is £0.3200, 59% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of £0.7300 per share, and 0 of the 10 models we run sit above the £0.7750 price.
Bear case: the Asset-Based group reads lowest at £0.1200, and 10 of the 10 models stay below the price. Data coverage for this calculation is low.
Scenario range: £0.2400 (bear) to £0.4000 (bull), the price of £0.7750 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Arecor Therapeutics PLC reported revenue of £1.7M in FY2025 versus £1.2M in FY2021, a compound +10.3%/yr. Reported net income was £664K in FY2025.
Key figures
Market cap £34.6M Micro · P/E ratio 77.5 · P/S ratio 30.0 · EPS (TTM) £0.0100 · Net margin 38.7% · Return on equity −1.4% · Return on assets (EBIT) −64.3% (5-year average) · Operating margin −1,630%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 35% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −59%, AREC screens richer than that median.
Fair Value models
Bear£0.2400Fair Value £0.3200Bull£0.4000
Price £0.7750 · Downside -58.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (£0.0086 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+63.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.5%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.6%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−201.9% (2020) → −268.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
News mood ⓘNews mood, the average tone of recent news (14 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Compare Arecor Therapeutics PLC with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−58.7% · Below median
Profitability
Return on assets8.2% · Top 25%
Net margin (12 months)21.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−80.9% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)77.5× · Priciest 25%
P/B5.36× · Priciest 25%
P/S (12 months)38.85× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Arecor Therapeutics PLC (AREC) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of £0.3200 versus a price of £0.7750, about 59% lower (overvalued).
What is the fair value of AREC?
Our model-based fair value for Arecor Therapeutics PLC is £0.3200 (as of Nov 9, 2026), built from audited fundamentals. The current price: £0.7750.
What is the quality score of AREC?
Arecor Therapeutics PLC has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Arecor Therapeutics PLC (AREC)?
Our model-based price target is the fair value of £0.3200 (as of Nov 9, 2026) from 10 valuation models. Cautious scenario £0.2400, optimistic scenario £0.4000. It is a calculation from audited fundamentals, not an analyst target.
What is the Arecor Therapeutics PLC stock forecast for 2026?
Our models put fair value at £0.3200, about 59% lower versus a price of £0.7750 (overvalued). Cautious scenario £0.2400, optimistic scenario £0.4000. The calculation is refreshed regularly with new filings.
What is the revenue of Arecor Therapeutics PLC (AREC)?
Arecor Therapeutics PLC reported trailing-twelve-month revenue of about £890K (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Arecor Therapeutics PLC (AREC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Arecor Therapeutics PLC it is £0.3200 per share (as of Nov 9, 2026), against a price of £0.7750. It is the blended result of 10 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Arecor Therapeutics PLC stock overvalued or undervalued in 2026?
As of Nov 9, 2026, AREC trades above its calculated fair value: price £0.7750, fair value £0.3200, a gap of about −59% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AREC?
No. The price is what the market pays today (£0.7750); the fair value is what the company's own numbers justify (£0.3200). For Arecor Therapeutics PLC the two are £0.4550 per share apart. That gap is exactly why we show both numbers side by side.
How much is Arecor Therapeutics PLC worth?
The market values Arecor Therapeutics PLC at about £34.6M (market capitalisation, as of Nov 9, 2026). Per share that is £0.7750; our models calculate a fair value of £0.3200 per share.
What do the bullish and bearish scenarios say about AREC?
Our models span a range for Arecor Therapeutics PLC: cautious scenario £0.2400, base £0.3200, optimistic £0.4000 per share (as of Nov 9, 2026, price £0.7750). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AREC?
Arecor Therapeutics PLC trades at a price-to-earnings ratio of 77.5 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of £0.3200 is built from several models across several years. Other multiples: P/B 5.4, P/S 38.9.
How solid is the balance sheet of Arecor Therapeutics PLC (AREC)?
Balance-sheet figures for Arecor Therapeutics PLC (as of Nov 9, 2026): return on equity −1.4%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is AREC from its 52-week high?
Arecor Therapeutics PLC trades at £0.7750, about 16% below its 52-week high of £0.9250 and 35% above the low of £0.5750 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of £0.3200 is for.
Which stocks are comparable to Arecor Therapeutics PLC?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Arecor Therapeutics PLC stock attractive at the current price?
The data as of Nov 9, 2026: price £0.7750, calculated fair value £0.3200 (−59%), Quality Score 55/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AREC calculated?
We run Arecor Therapeutics PLC through 10 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of £0.3200 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Arecor Therapeutics PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Arecor Therapeutics PLC (AREC)?
The closing price on Nov 6, 2026 was £0.7750. Our model-based fair value is £0.3200, about 59% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Arecor Therapeutics PLC right now?
The price sits above even our optimistic bull case (£0.4000). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Arecor Therapeutics PLC
How large is the market capitalisation of Arecor Therapeutics PLC (AREC)?
The market capitalisation of Arecor Therapeutics PLC is £34.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Arecor Therapeutics PLC (AREC)?
The price-to-sales ratio of Arecor Therapeutics PLC is 30.0 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Arecor Therapeutics PLC (AREC)?
Earnings per share at Arecor Therapeutics PLC are £0.0100 (price ÷ EPS = P/E 77.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Arecor Therapeutics PLC (AREC)?
The net margin of Arecor Therapeutics PLC is 38.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Arecor Therapeutics PLC (AREC)?
The return on equity (ROE) of Arecor Therapeutics PLC is −1.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Arecor Therapeutics PLC (AREC)?
On an EBIT basis the return on assets of Arecor Therapeutics PLC is −64.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Arecor Therapeutics PLC (AREC)?
The operating margin of Arecor Therapeutics PLC is −1,630% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Arecor Therapeutics PLC (AREC)?
Revenue at Arecor Therapeutics PLC is growing −80.9% versus a year earlier (3y avg +63.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Arecor Therapeutics PLC (AREC) generate?
The free cash flow of Arecor Therapeutics PLC is −£2.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Arecor Therapeutics PLC (AREC) hold?
Arecor Therapeutics PLC holds more cash than debt, £2.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Arecor Therapeutics PLC in the live analysis
One click puts Arecor Therapeutics PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026